|
|
11th February
2012 - New research
PARDOPRUNOX CLINICAL TRIAL RESULTS
Parkinsonism Related Disorders [2012] Feb 6 [Epub
ahead of print] (O.Rascol, J.Bronzova, R.A.Hauser, A.E.Lang, C.Sampaio,
A.Theeuwes, S.V.van de Witte)
Complete abstract
An assessment was made of the efficacy and safety of Pardoprunox in people with
Parkinson's Disease who were experiencing motor fluctuations. Pardoprunox is a
new partial dopamine agonist being developed that unusually combines two effects as if it were two
distinct but combined drugs : partially stimulating dopamine, whose deficiency
causes Parkinson's Disease, and fully stimulating serotonin. It was thought that
Pardoprunox could avoid some of the severe side effects that other dopamine agonists cause
by lessening the effect of dopamine when dopamine activity is high. This study
follows on from two previous assessments of Pardoprunox. For more information
concerning the earlier studies
click here.
Pardoprunox was taken in dosages of up to 42mg per day.
Pardoprunox reduced OFF time by 1 hour 37 minutes per day, but even a placebo
reduced the OFF time by 55 minutes per day. So the actual benefit of Pardoprunox beyond that of a placebo was a
reduction in OFF time of only 42 minutes per day. Pardoprunox made no
significant difference to scores on the PDQ-39, which assesses Parkinson's
Disease symptoms. There was a high drop-out rate (37% of people) due to adverse
events suggesting that the selected dose range may have been too high, or that
the increase in dose may have been too rapid. For
more current news go to
Parkinson's Disease News.
E-MAIL NOTIFICATION : If you would like to be
notified by e-mail when any new articles are added to Parkinson's Disease News, please merely
e-mail
[email protected] with the message
"subscribe". No form of identity is required. E-mail addresses are
not used for any other purpose.
|
|
|
Parkinson's Disease News details
all significant new research, news reports, new books, and new resources
concerning Parkinson's Disease and those medical disorders that often coincide
with Parkinson's Disease. It is compiled from an analysis of all newly
published research, news reports, new clinical trials, all newly published
books, and new web sites. A summary and analysis of the new research are
provided, as well as links to the complete abstracts and news reports

|